Innovator IBD 50 ETF (FFTY)
| Assets | $61.91M |
| Expense Ratio | 0.80% |
| PE Ratio | 29.59 |
| Shares Out | 2.35M |
| Dividend (ttm) | $0.26 |
| Dividend Yield | 1.06% |
| Ex-Dividend Date | Dec 31, 2024 |
| Payout Ratio | 31.44% |
| 1-Year Return | -10.30% |
| Volume | 130,892 |
| Open | 25.33 |
| Previous Close | 26.37 |
| Day's Range | 24.18 - 25.26 |
| 52-Week Low | 22.96 |
| 52-Week High | 34.26 |
| Beta | 1.26 |
| Holdings | 51 |
| Inception Date | Apr 9, 2015 |
About FFTY
Fund Home PageThe Innovator IBD 50 ETF (FFTY) is an exchange-traded fund that is based on the IBD 50 TR index. The fund tracks an index of 50 US-listed stocks with aggressive growth characteristics. Holdings are selected based on fundamental and technical rankings FFTY was launched on Apr 9, 2015 and is issued by Innovator.
Top 10 Holdings
35.54% of assets| Name | Symbol | Weight |
|---|---|---|
| Zai Lab Limited | ZLAB | 3.97% |
| BeiGene, Ltd. | ONC | 3.87% |
| Alignment Healthcare, Inc. | ALHC | 3.86% |
| Agnico Eagle Mines Limited | AEM | 3.80% |
| ADMA Biologics, Inc. | ADMA | 3.63% |
| Catalyst Pharmaceuticals, Inc. | CPRX | 3.52% |
| Axsome Therapeutics, Inc. | AXSM | 3.33% |
| Alamos Gold Inc. | AGI | 3.28% |
| Grindr Inc. | GRND | 3.19% |
| Arcutis Biotherapeutics, Inc. | ARQT | 3.09% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 31, 2024 | $0.25908 | Jan 2, 2025 |
| Dec 28, 2023 | $0.15529 | Jan 2, 2024 |
| Oct 26, 2023 | $0.00214 | Oct 30, 2023 |
| Dec 29, 2022 | $0.60033 | Jan 3, 2023 |
| Dec 30, 2021 | $0.09915 | Jan 3, 2022 |
| Dec 28, 2017 | $0.05684 | Jan 2, 2018 |
News
FFTY: Uneven Recovery After Cataclysmic 2022
FFTY has an intricate, labyrinthine index-based strategy with a focus on growth stocks. The reality is more complex. Incepted in 2015, FFTY outperformed IVV only in 2017. After a 52.4% decline in 2022...
FFTY: Deeper Delve Into The Portfolio, No Reason To Upgrade
Leveraging the CAN SLIM Investing System, FFTY targets the 50 most promising stocks selected from around the 7,000-strong universe. The article provides an update on FFTY's performance and current fac...
FFTY: A Silver Lining On The Valuation Side, Vulnerabilities Elsewhere
FFTY is an extremely high-turnover, expensive ETF with poor risk dispersion owing to the high-conviction strategy with holdings limited to just 50 names. What I appreciate is that FFTY mixes the profi...
FFTY: With Momentum Weak, Avoid This ETF
FFTY ETF contains 50 companies curated by Investors Business Daily according to their CAN SLIM system developed by IBD's founder Bill O'Neil. This system selects companies on the basis of factors like...
FFTY: Patchy Returns Surprise Despite Solid Strategy
FFTY is a growth-heavy mid-caps-leaning fund with gargantuan turnover owing to weekly reconstitutions. The index it tracks encompasses 50 high-conviction picks selected from the list of around 7,000 e...
Franklin Custodian Funds' Dynatech Fund: Don't Buy This Dip – Legacy Fund Ratings Are Misleading
A deep dive into this fund's holdings reveal a portfolio that is inferior to its benchmark and the S&P 500.
